TYPHOID FEVER
TO DETERMINE THE OUTCOME OF COMBINATION VERSUS MONO ANTI-BIOTIC THERAPY IN TYPHOID FEVER.
DOI:
https://doi.org/10.29309/TPMJ/2018.25.01.535Keywords:
Salmonella Typhi, Blood Culture, Widal Test, Typhidot, Ciprofloxacin, CeftriaxoneAbstract
Typhoid fever caused by Salmonella Typhi, is the most common gastrointestinal
infectious disease affecting all over the world particularly in Asia where more than 13 millions
peoples are affected. Six hundred thousand (600.0000) death occur annually all over the world.1
Nearly eighty percent (80%) occur in Asia. The main source of infection is contaminated food, water
and poor hygiene. Monotherapy, emerging drug resistance and long duration drug treatment
is further complicating the problem.2 Approach to combination antibiotic therapy and shortest
duration of treatment is needed. Period: January 2016 to June 2016. Objectives: To determine
the outcome of combination versus mono anti-biotic therapy in typhoid fever. Study Design:
A prospective descriptive study. Place of Study: Mohi-Ud-Din Teaching Hospital Mirpur AJK.
Results: Among 138 patients, the relapse rate was high in patients treated with monotherapy
as compared combination therapy. Conclusion: Relapse is more common in ciprofloxacin and
ceftriaxone groups. Among combination therapy, (ciprofloxacin and ceftriaxone,) relapse was
less common. When relapsed patients were retreated with combination therapy, the patients
were completely cured.